Anatomy and physiology of the human eye: Effects of mucopolysaccharidoses disease on structure and function - a review

Clinical and Experimental Ophthalmology

Volumn 38, Issue SUPPL. 1, 2010, Pages 2-11

  Willoughby, Colin E ^a   Ponzin, Diego ^b   Ferrari, Stefano ^b   Lobo, Aires ^c   Landau, Klara ^d   Omidi, Yadollah ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b The Veneto Eye Bank Foundation   (Italy)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anatomy; Eye disease; Mucopolysaccharidosis; Physiology; Review

Indexed keywords

BEVACIZUMAB; EYE DROPS; FLUOCINOLONE ACETONIDE; GALSULFASE; GANCICLOVIR; GLYCOSAMINOGLYCAN; PEGAPTANIB; RANIBIZUMAB; RIBOZYME; SMALL INTERFERING RNA;

ANTISENSE THERAPY; BIOACCUMULATION; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; BOWMAN MEMBRANE; CELL ENCAPSULATION; CELL THERAPY; CHOROID; CLINICAL FEATURE; CONJUNCTIVA; CORNEA; CORNEA EPITHELIUM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG UPTAKE; ENZYME REPLACEMENT; EYE; EYE DISEASE; GENE THERAPY; GENETIC ENGINEERING; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MUCOPOLYSACCHARIDOSIS; NONHUMAN; OPTIC DISK; OPTIC NERVE; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHOTORECEPTOR; PIGMENT EPITHELIUM; RETINA; RETINA BLOOD FLOW; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; REVIEW; SCLERA; SIGNAL TRANSDUCTION; VISION; VITREOUS BODY;

EID: 77955402493     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02363.x     Document Type: Review

References (41)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-52. Scriver CR, Beaudet ALSly WSValle D. In, eds., 8th, edn. Chapter 136, New York, McGraw-Hill Medical Publishing Division
2. Biswas J, Nandi K, Sridharan S, Ranjan P. Ocular manifestation of storage diseases. Curr Opin Ophthalmol 2008, 19:507-11.
3. Collins MLZ, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology 1990, 97:1445-9.
4. Ashworth JL, Biswas S, Wraith E, Lloyd IC. The ocular features of the mucopolysaccharidoses. Eye 2006, 20:553-63.
5. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006, 51:1-17.
6. Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y. Ocular drug delivery; impact of in vitro cell culture models. J Ophthalmic Vis Res 2009, 4:238-52.
7. Müller LJ, Marfurt CF, Kruse F, Tervo TMT. Corneal nerves: structure, contents and function. Exp Eye Res 2003, 76:521-42.
8. Rüfer F, Schröder A, Erb C. White-to-white corneal diameter: normal values in healthy humans obtained with the Orbscan II topography system. Cornea 2005, 24:259-61.
9. Van Buskirk EM. The anatomy of the limbus. Eye (Lond) 1989, 3:101-8. Pt 2
10. Farjo AA, McDermott ML, Soong HK. Corneal anatomy, physiology, and wound healing. Ophthalmology 2009, 203-8. Yanoff M, Duker JS, In, eds., 3rd, edn., Edinburgh, Mosby Elsevier, Elsevier Inc.
11. Daniels JT, Dart JKG, Tuft SJ, Khaw PT. Corneal stem cells in review. Wound Repair Regen 2001, 9:483-94.
12. Dua HS, Shanmuganathan VA, Powell-Richards AO, Tighe PJ, Joseph A. Limbal epithelial crypts: a novel anatomical structure and a putative limbal stem cell niche. Br J Ophthalmol 2005, 89:529-32.
13. Majo F, Rochat A, Nicolas M, Jaoude GA, Barrandon Y. Oligopotent stem cells are distributed throughout the mammalian ocular surface. Nature 2008, 456:250-4.
14. Maurice DM. The transparency of the corneal stroma. Vision Res 1970, 10:107-8.
15. Boote C, Dennis S, Newton RH, Puri H, Meek KM. Collagen fibrils appear more closely packed in the prepupillary cornea: optical and biomechanical implications. Invest Ophthalmol Vis Sci 2003, 44:2941-8.
16. Johnson DH, Bourne WM, Campbell RJ. The ultrastructure of Descemet's membrane. I. Changes with age in normal corneas. Arch Ophthalmol 1982, 100:1942-7.
17. Gallagher B, Maurice D. Striations of light scattering in the corneal stroma. J Ultrastruct Res 1977, 61:100-14.
18. Miller NR, Newman NJ. Embryology, anatomy, and physiology of the afferent visual pathway. Walsh & Hoyt's Clinical Neuro-Ophthalmology 2005, 3-82. Miller NR, Newman NJ. eds, In, eds., Vol. 1, 6th, edn., Philadelphia, PA, Lippincott Williams & Wilkins
19. Schubert HD, Marmor MF, Roh S, Weiter JJ. Structure and function of the neural retina: Retinal pigment epithelium: Retinal and choroidal circulation: Ophthalmology 2009, 511-21. Yanoff M, Duker JS, In, eds., 3rd, edn., Edinburgh, Mosby Elsevier, Elsevier Inc.
20. Masland RH. The functional architecture of the retina. Sci Am 1986, 255:102-11.
21. Young RW. The renewal of rod and cone outer segments in the rhesus monkey. J Cell Biol 1971, 49:303-18.
22. Foulds WS. Do we need a retinal pigment epithelium (or choroid) for the maintenance of retinal apposition? Br J Ophthalmol 1985, 69:237-9.
23. Grierson I, Hiscott P, Hogg P, Robey H, Mazure A, Larkin G. Development, repair and regeneration of the retinal pigment epithelium. Eye 1994, 8:255-62. Pt 2
24. Reh TA, Levine EM. Multipotential stem cells and progenitors in the vertebrate retina. J Neurobiol 1998, 36:206-20.
25. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006, 58:1131-5.
26. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv 2008, 5:567-81.
27. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006, 58:1136-63.
28. Klaassen I, Hughes JM, Vogels IM, Schalkwijk CG, Van Noorden CJ, Schlingemann RO. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Exp Eye Res 2009, 89:4-15.
29. Stitt AW, Anderson HR, Gardiner TA, Bailie JR, Archer DB. Receptor-mediated endocytosis and intracellular trafficking of insulin and low-density lipoprotein by retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 1994, 35:3384-92.
30. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010, 5:5.
31. Pastores GM. Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I. Expert Opin Biol Ther 2008, 8:1003-9.
32. Le MG, Stieger K, Smith AJ. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007, 14:292-303.
33. Bainbridge JWB, Smith AJ, Barker SS. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358:2231-9.
34. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007, 4:371-88.
35. Maguire AM, Bennett J. Gene therapy for retinal disease. Intraocular Drug Delivery 2006, 157-73. Jaffe GJ, Ashton PPearson PA. In, eds., New York, Taylor & Francis Group, LLC
36. Tao W, Wen R, Laties A, Aguirre GD. Cell-Based Delivery systems: development of encapsulated cell technology for ophthalmic applications. Intraocular Drug Delivery 2006, 111-28. Jaffe GJ, Ashton P, Pearson PA, In, eds., New York, Taylor & Francis Group, LLC
37. Kenyon KR. Ocular manifestations and pathology of systemic mucopolysaccharidoses. Birth Defects Orig Artic Ser 1976, 12:133-53.
38. Alroy J, Haskins M, Birk DE. Altered corneal stromal matrix organization is associated with mucopolysaccharidosis I, III and VI. Exp Eye Res 1999, 68:523-30.
39. Cantor LB, Disseler JA, Wilson FM. Glaucoma in the Maroteaux-Lamy syndrome. Am J Ophthalmol 1989, 108:426-30.
40. Schumacher RG, Brzezinska R, Schulze-Frenking G, Pitz S. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol 2008, 38:543-50.
41. Ashworth JL, Kruse FE, Bachmann B. Ocular manifestations in the mucopolyscaccharidoses. Clin Experiment Ophthalmol 2010, 38(S1):12-22.